Physical activity (PA) is essential for the maintenance of health across virtually all therapeutic areas and is often recognized as a ‘sixth vital sign’. While it is becoming clear that relying on point-in-time, clinic-based walking tests are insufficient to accurately capture physical function in a meaningful way, digital health technologies (DHTs) present an opportunity to measure activity in real life.
The Digital Medicine Society (DiMe) is currently leading a pre-competitive collaboration to define a core set of digital clinical measures for physical activity (PA) across therapeutic areas. With more than 70 unique digital endpoints for PA currently being used, we aim to move away from innovating in siloes and leverage multi-stakeholder collaboration to answer tough digital measures questions, demonstrating a process of what good looks like. Understanding which digital measures matter for physical activity can speed up the development of therapeutics and enable the field to respond swiftly and meaningfully, equipped with the right evidence for decision-making.
While DHTs have come a long way and there is clear signal within digital measures to have the ability to detect pregnancy as well as monitor prenatal wellbeing, many of the existing commercially available health and wellness tools are not designed to be inclusive of the realm of maternal and fetal medicine. This webinar explored personal use cases and design & development expert opinions for how currently available tools can and have been used within this space and where there are glaring unmet needs and opportunities for the industry to improve connected care.
The potential benefits of a remodeled delivery system based on virtual first care (V1C) are tremendous – in terms of patient access and experience, workforce efficiency, and improved health and economic outcomes. At the same time, in the post-pandemic era, solutions of varying quality and reliability are flooding the market. Without consistent evaluation criteria to guide builders and buyers towards high-quality V1C, the trust of this movement is at stake.
To address this need, IMPACT, the multi-stakeholder V1C initiative co-hosted by the Digital Medicine Society (DiMe) and the American Telemedicine Association (ATA) has developed an industry-vetted V1C Checklist. This tool defines essential competencies and hallmarks of high quality, trustworthy V1C.
In this historical moment the gap between legislation that does not yet exist and institutional practices that are not yet regulated leaves people without the essential protections they need to maintain their privacy and their basic rights. This leaves online patient communities vulnerable to privacy violations, identify theft, scams, discrimination, disinformation, ad targeting, harassment and other forms of exploitation that can steal their security and undermine their health, wealth and overall well-being of patient populations.
This panel explored how The Light Collective, a network of tech savvy patient communities, came together to address this problem. Their founder, Andrea Downing, discussed their published research on Meta Pixel and cross-site tracking that sparked congressional investigations, and drove HHS guidance.
In 2023, one thing is evident – A fit-for-purpose regulatory strategy is a good business strategy for digital health innovators!
DiMe’s Digital Health Regulatory Pathways project team has developed tools and resources for innovators.
Leading regulatory experts from across the digital health field discussed how:
1. You can use regulatory strategy to become a
commercial differentiator for your digital health solutions
2. To bridge modern-day software-based digital health
products with the new and past FDA regulations
3. You can identify the right regulatory pathway for your
medical product to impact reimbursement, patient adoption,
and health outcomes
The call for diversifying clinical trials and creating a more equitable and inclusive clinical trials industry has gotten louder. Are you ready to take action?
DiMe’s Diversity, Equity, and Inclusion in Digitized Clinical Trials project team is launching resources demonstrating how digital tools can be used to tackle many of the challenges facing clinical trials, from patient engagement, recruitment, and retention to more robust data collection and better outcomes.
Join us for the launch of these resources, insights from FDA Commissioner Rob Califf, and an inspiring discussion on how you can use these new tools, now, to advance DEI in clinical trials.
We have the opportunity to advance health equity and transform the clinical trials industry. Join DiMe’s team of leading experts to learn how you can implement these resources, now.
Digital health innovation has grown exponentially in recent years. Teams developing digital health products and technologies have developed their products using unique, multi-faceted programming modalities to support an evolving set of features to meet the diverse needs of user populations. While this has enabled products to be fit-for-purpose, this has also resulted in disparate products that exacerbate the challenges of interoperability, making retrofit and digital transformation more challenging.
Leveraging heterogeneous computing with unified cross architecture programming allows digital health products to utilize open source industry specifications that allow software application development to be hardware agnostic, which in turn enables product developers and healthcare systems using those products to deploy innovative solutions off-the-shelf on their existing heterogeneous infrastructure. As a result, the barrier to entry for many often overlooked consumers is reduced, ensuring that no matter where it’s implemented, an innovative product can remain patient-centric.
Watch as we discuss how digital health product teams can deliver groundbreaking solutions that are both innovative and equitable. Thought leaders at Intel, Canon Medical, and Oracle discuss how they’ve implemented a unified cross programming model for heterogeneous computing to increase software innovation and expand market access to digital health technologies to deliver patient-centric care solutions to those in need.
By now most of us have participated in a video healthcare visit, a result of the sweeping pivot to telemedicine driven by the pandemic. But how much did the pandemic really accelerate the digitization of healthcare delivery? How widespread is awareness and implementation of truly transformative, digitally-enabled care that improves access, experience, and outcomes, what we call, Virtual-First Care?
Omada Health, in partnership with DiMe and with support from Rock Health, surveyed over 750 decision-makers in the healthcare purchaser industry to find out. The results of this study show surprising variation across the purchaser community regarding adoption drivers, program priorities, and, importantly, reveal fundamental confusion about what is meant by ‘virtual care’ and the cost, quality, and access benefits it can deliver for patients, purchasers, and providers.
On December 1st, leaders from across the healthcare ecosystem discussed the results of this benchmarking study of employers and health plans.
Thought leaders representing virtual first care, medical providers, employers and healthcare investors will reflect on implications of the survey results and together share insights for strategies and actions that will enable full potential of virtual first care.
Everyone’s talking about the lack of diversity, equity, and inclusion in clinical trials. The FDA issued draft guidance to provide recommendations to help clinical trial sponsors develop a Race and Ethnicity Diversity Plan. Some House Democrats are also pushing for Congressional legislation to secure more representation in clinical trials. We all recognize the need to do something about it, but who’s going to lead the efforts? Who’s going to be accountable for increasing diversity in clinical trials?
Leaders from across the clinical trials ecosystem give an update on the Diversity, Equity, and Inclusion in Digitized Clinical Trials project, and an in-depth discussion on what different stakeholders can do to ensure digital technologies are used to increase diversity, equity, and inclusion in clinical trials.
V3 combines widely recognized practices from both software and clinical development to establish the shared foundation for evaluating whether digital clinical measures are fit for purpose. Since its publication in 2020, V3 has been adopted by over 45 teams developing and deploying digital clinical measures as well as the European Medicines Agency (EMA).
But what has the process for adoption been within organizations? And how have organizations upleveled their processes around evaluation of digital sensing products, algorithms, and clinical use cases across the board to embed V3 into a systematic approach?
Listen to learn more about how companies have applied V3 to ensure their digital measures are fit for purpose. Hear from digital leaders at Takeda and Koneksa about how their organizations have implemented this framework, and how it’s helped them navigate the complexity of digital measurement more thoughtfully and effectively.
For the first time ever, we have a blueprint for developing and deploying digital endpoints in medical product development.
On Sept. 8, industry leaders Abbvie, Janssen, Novartis, Pfizer, UCB, Advancing Innovation in Dermatology, Almirall, GSK, Leo Pharma, Eli Lilly, and Sanofi collaborated to research the meaningfulness of nocturnal scratching to atopic dermatitis (AD) patients and developed new resources for deploying scratch digital measures in clinical trials.
In addition to addressing an unmet need for AD patients, this work lays the groundwork for advancing the use of digital endpoints in medical research and care. Event attendees learned about:
DiMe’s own, Lucy Cenakova, moderated a panel with Matthew Diamond, Chief Medical Officer at FDA, and Thorsten Vetter, Senior Scientific Officer at EMA.
Explore the Nocturnal Scratch resources
View the Nocturnal Scratch launch Webinar Slides
Sensor data has the potential to transform how we define health and disease and increase our ability to make better decisions, faster, across patient care and clinical research.
To realize this potential at scale, organizations from across the tech and healthcare sectors have developed an open access toolkit through the Digital Medicine Society (DiMe) Sensor Data Integrations project. Join us on July 18 as experts from Amazon Web Services, Anthem, Evidation, FDA, IEEE, Moffitt Cancer Center, Human First, Medable, Open mHealth, Oracle, Takeda, Savvy Co-op, and the Veteran’s Health Administration report on the state of sensor data use in healthcare and unveil these new resources for the first time.
Micky Tripathi, National Coordinator for Health Information Technology at the U.S. Department of Health and Human Services, kicked off this public launch event with opening remarks.
Explore the Sensor Data Integrations resources
View the SDI launch Webinar Slides
IMPACT is a pre-competitive industry collaborative co-hosted by the American Telemedicine Association (ATA) and the Digital Medicine Society (DiMe) dedicated to expanding high quality, evidence-based virtual first care (V1C) for patients, healthcare providers, and payers to improve clinical and health economic outcomes, enhance access, and provide a better overall patient experience. IMPACT members work together to advance the most pressing opportunities for V1C.
Care transitions between V1C providers and other practitioners and sites of care (both virtual and bricks and mortar) present an opportunity to optimize access, patient and provider experience, efficiency, and clinical outcomes.
Join us for this 90-min launch event to learn about the overarching vision of IMPACT, meet experts from the IMPACT Steering Committee guiding its direction, and get a first look at a new suite of resources and best practices to optimize care transitions across the care continuum that will facilitate full integration of V1C into the healthcare delivery ecosystem.
Learn more at impact.dimesociety.org
In the quickly evolving ecosystem of digital medicine, interdisciplinary collaborative forums will be critical for solving challenges facing the healthcare sector. DiMe partnered with FDA’s Center for Devices and Radiological Health (CDRH), to host the Digital Health Measurement Collaborative Community (DATAcc).
DATAcc convened a broad range of stakeholders to modernize the way we measure and define health and disease using digital approaches and technologies. The two inaugural projects are modeled on the FDA’s device development process. One project identifies and supports the application of inclusive elements at each phase of the digital measurement product development process. The second operationalizes inclusion in the deployment of digital health measurement products across contexts of use.
In this 2-hour launch event, learn about the overarching vision of DATAcc, meet the experts from the DATAcc Steering Committee guiding its direction and the project teams who were instrumental in developing these two suites of products. Get a first look at a suite of products that will help the field make great strides of addressing historic biases, realizing the broad benefits of inclusivity, and improving lives, for everyone.
View the DATAcc Webinar Slides
Listen in to the recording from our DiMe Webinar, “Powering Digital Health Innovation through Successful VC Funding” by Aaron Gani, CEO at BehaVR, Owen McCarthy, Co-founder of MedRhythms Inc, and Ben Lewis, CEO of Limbix.
The right investment strategy is critical for long-term success, and digital health is very much a long-term industry. How can you balance selecting the best-fit investor and your Round One valuations? Check out this discussion with the experts! This webinar is proudly sponsored by First Republic Bank. DiMe proudly banks with Managing Director Anthony Cuadro, who specializes in startups, alternative investments, life sciences, and Medtech banking. Interested in doing business with FRB? Contact Anthony at acuadro@firstrepublic.com to get started!
Powering Digital Health Innovation through Successful VC Funding: Slide Deck
Our industry has spent years working to develop the evidentiary best practices to try and ensure that regulators accept evidence from digital endpoints in support of new drug approvals. But, to date, we’ve thought very little about how payers and HTAs may consider data from digital endpoints in reimbursement and pricing decisions.
In this webinar, DiMe and our partners from Anthem, Biogen, Eli Lilly, Evidation, Janssen, Merck, Pfizer, and Savvy Co-op introduced a new suite of resources to support evidence generation strategies for the use of data generated by digital endpoints in value and reimbursement discussions for new drugs.
In the digital era of healthcare, cybersecurity must be a priority for every healthcare system, tech developer, clinician and patient. But where can we find solutions ready to use today as the threat or cyber harms loom large? The US Federal Cybersecurity and Infrastructure Agency (CISA) has an open access suite of resources designed to support the industry in maintaining cybersecurity and many are fit-for-purpose for healthcare. Join us on March 15 at 11 am ET as Tom Millar, Senior Advisor at Cybersecurity and Infrastructure Security Agency (CISA), walks us through resources available to you today as you protect your systems and patients from cyberharms in the digital era.
Mr. Millar has served in CISA for 10 years, working to strengthen the agency’s information-sharing capabilities, increasing the level of public, private, and international partner engagement, and supporting initiatives to improve information exchange by both humans and machines, such as the standardization of the Traffic Light Protocol and the development of the Structured Threat Information eXpression. Prior to his cybersecurity career, he served as a linguist with the 22nd Intelligence Squadron of the United States
Air Force.
View the CISA Webinar Slide Deck
Listen in to Part 2 of “Putting Digital Health Into Practice | A CTA-DiMe Seminar Series.” This session focused on the opportunities and challenges tech companies are experiencing as they navigate the complex healthcare system
Panelists:
Moderator:
View the CTA-DiMe presentation
The Consumer Technology Association (CTA) and Digital Medicine Society (DiMe) partnered to co-host a two-part seminar series focused on solutions to the most pressing challenges impeding the successful digitization of healthcare at scale. Listen in as leading experts from healthcare and technology came together to deliver ‘real talk’ on Addressing Bias in the Evolving Landscape of AI in Health Care
This session explored the role of bias related to the use of data for AI in health care solutions and how clinicians, tech companies, and other stakeholders are learning mitigation approaches as the AI landscape evolve
Panelists:
Moderator:
Join DiMe CEO, Jennifer Goldsack, and COO, Claire Meunier for an update on the DiMe project portfolio, key activities planned for 2022, and their take on the greatest challenges our field faces in advancing the safe, effective, ethical, and equitable use of digital medicine to optimize health.
January 2022 Webinar Slide Deck
COVID-19 has highlighted the inequity in digital medicine, specifically in low-resource settings. In this webinar, we bring experts Dr. Brinnae Bent, Dr. Christopher James, and Santosh Shevade together to discuss challenges that affect how digital medicine is implemented in low-resource settings, and current limitations in usability evaluation and research implementation that are further exacerbating disparities in digital medicine. The discussion will focus on the need to have patients as partners and will highlight recommendations on implementing research in low-resource settings. Equity in digital medicine is critical to the success of the field, and viewers will come away from the webinar with a better understanding of the current state of digital medicine in low-resource settings, and ways in which research and development can become more equitable.
December 2021 Webinar Slide Deck
The world of digital medicine and clinical trials is swiftly evolving. In order for scientific and technological innovation to be realized effectively, regulatory adaptation and reform need to keep pace.
This session examined the end-to-end clinical trial process and discusses some of the collaborations in the industry supporting teams right now. One such collaboration is the Association for Clinical Research Organization’s (ACRO) toolkit to advance decentralized clinical trials technology that is advancing the field, such as how technology is supporting clinical strategy and operations and catalyzing regulatory reform. Listen in to learn more about ARCO and the success of this project!
November 2021 Webinar Slide Deck
By generating solid clinical evidence, digital health vendors may increase confidence in the reproducibility of clinical trial data and claims (i.e., their capacity to deliver clinical value). This can help vendors establish trust and progress more rapidly from pilot partnerships to scaled deployments. Novel frameworks for clinical evidence assessment, incorporating the latest scientific methods for predicting clinical impact of digital health solutions, may help vendors develop compelling clinical validation strategies, support clinical trials and optimize their likelihood of growth.
October 2021 Webinar Slide Deck
As virtual first care (V1C) gains momentum, standard provider and vendor contracting models fail to account for the range of features and format of these services, leading to delays and challenges in contracting. Recognizing these breakdowns, IMPACT members from over 30 virtual first care, payer, funder, digital health, and services companies have come together to address the greatest barriers to V1C adoption at scale.
On October 1st IMPACT launched the Payer-V1C Contracting Toolkit – a suite of action-oriented resources, such as the Guide to Payer-V1C Model Contracting, Guide to V1C payment models, and V1C Coding Library. The toolkit will support alignment between payer’s systems and processes around new modalities of care to facilitate contracting and ultimately drive more effective adoption of V1C.
The meeting featured expert remarks by Saurabha Bhatnagar, Chief Health Officer, Commure. Donald Jones, Co-Founder of IMPACT also provided an expert V1C solution perspective based on his renowned digital health expertise and extensive advisory work in the field.
Claire Meunier, DiMe’s COO and Executive Lead on IMPACT then moderated a panel discussion featuring IMPACT members Joe Connolly, Co-Founder & CEO, Visana Health, Lucia Savage, Chief Privacy & Regulatory Officer, Omada Health, and Marcus Thygeson, Chief Health Officer, Bind Benefits.
IMPACT Payer-V1C Toolkit Public Meeting Slide Deck
Digital health is growing as a vital part of healthcare, and with a rise in data-driven solutions and digital platforms, digital health technology can be an accurate and efficient way to empower patients. Digital pills can measure medication intake data and report it to care teams in real time, providing a platform to engage with patients about their treatment plan. Patients face many challenges with medication adherence — from complex dosing regimens to access to the medications themselves — and high-quality, evidence based technology can help. In this session, we discussed how even small care teams can use digital pill technology to help their patients stay on track with their therapy in real time, discover how to transform engagement with their patients, and uncover the wide-reaching clinical and commercial potential for this type of digital transformation. Hear from an expert patient, clinician, regulatory professional, pharma executive, and RWE researcher on how we can build better digital pills to support care teams and the patients they serve.
September 2021 Webinar Slide Deck
Digital endpoints offer enormous promise to transform medical product development and the reach of new therapies to all patients, including individuals typically underrepresented in clinical research.
This summer, DiMe is collaborating with colleagues at the Clinical Trials Transformation Initiative (CTTI), and Transcelerate to highlight the best resources available to sponsors, digital product manufacturers, and researchers committed to harnessing the power of digital clinical trials to advance the safe, effective, ethical, and equitable use of digital technologies to improve lives through new approaches to medical product development. Register now for the first session, led by DiMe CEO Jen Goldsack and moderated by Rachel Chasse, in the three-part series from CTTI, DiMe, and TransCelerate.
August 2021 Webinar Slide Deck
Companies are learning that in order to create truly patient-centered solutions, they need to incorporate patient insights. Yet, many people—from small startups to large pharmaceutical companies—don’t know where to start. Throw in a global pandemic, and it can seem even more daunting to engage patients. But it doesn’t have to be, and in this session, we will discuss how even a small team can get started. Listen in to the recording of our July webinar to learn how both qualitative and quantitative patient insights can enhance both clinical research and digital product development, which can lead to new features, a better patient experience, and improved outcomes.
Click here to listen to the recording!
Click here to view the presentation slides
Digital medicine has revolutionized healthcare, but what does this mean for the future of pharmacists? Pharmacists are the first point of care for many people: how will they play a pivotal role in adopting digital products to optimize and advance patient care? With advancements in digital medicine, exciting opportunities emerge for pharmacists to evolve and expand their roles. Listen in to the recorded panel discussion with Aspen RxHealth and RxE2 on how they are innovating the pharmacy world today, and what their vision is for the future.
Click here to listen to the recording!
Click here to view the presentation slides
Listen in to DiMe’s successful launch of “The Playbook: Driving Adoption, featuring over 100 new action-oriented resources that make it easier for you to:
Amy Abernethy, former principal deputy commissioner of the FDA, kicked off our launch event with opening remarks on how to use digital innovation to improve lives. We then unveiled “The Playbook: Driving Adoption” through a series of 9 different panels of experts. You can experience each panel individually or as a complete event on our Tour of Duty, “The Playbook: Driving Adoption” Playlist.
Click here to listen to the playlist!
Curious how you might translate a career in digital medicine or healthcare to public service opportunities? Presidential Innovation Fellows (PIF) is one way to join the federal government and make an impact, and applications are open now!
Presidential Innovation Fellows join the federal government for one to two years as entrepreneurs-in-residence at federal agencies! From COVID-19 to veterans’ benefits f to human-centered design, PIFs will share their experience applying their skills and leadership in partnership with federal leaders. Join a panel of current PIFs and learn about how you could bring vital digital medicine and healthcare experience to key initiatives across the federal government. Apply to PIF through May 14 at apply.pif.gov!
Click here to listen to the recording!
The ‘IMPACT’ initiative, co-created by DiMe and ATA, aims to go beyond conventional telemedicine efforts that are layered on top of existing healthcare organizations, and to instead develop solutions that its organizers call “virtual-first.” Virtual first medical care combines digital medicine, communications technology, and clinical expertise for patient-centered healthcare. IMPACT is a pre-competitive collaboration of leading digital health companies, investors, payers, and consultants dedicated to supporting virtual-first medical organizations and their commitment to patient-centric care.
Click here to listen to the recording!
Click here to view the presentation slides
Fully half of the world’s population goes without needed healthcare. To improve global access to care, StartUp Health’s innovative group of Health Transformers develop and deploy radical digital medicine solutions that address delivery, cost, geography, and technology.
Listen in to the recording as our panel of experts discuss with three Health Transformers about how they are working towards the Health Moonshot goals of improving global access to care with digital medicine products:
Miguel Johns, CEO of DiabetesCare — providing global diabetes care powered by machine learning
Bryan Mezue, CEO of Lifestores Healthcare — deploying tech-enabled products to create ‘pharmacies of the future’ in Nigeria
Areva Martin, CEO of Butterfly Health — delivering a digital therapeutic for behavioral health providing culturally-sensitive mental healthcare to underrepresented populations in the United States
Click here to listen to the recording!
Click here to view the presentation slides
This year, Rock Health and Dr. Ivor Horn teamed up to launch a new Diversity in Digital Health initiative, with a survey to baseline the racial and ethnic diversity of leadership at digital health startups. Listen in to the recording of Rock Health COO, Megan Zweig, as she shares key findings from the 678 digital health startup leaders who completed the survey and perspectives on how the digital health sector can work toward addressing disparities in entrepreneurial leadership, non-capital support, and funding. Komathi Stem, COO of Glooko, provides her experience as a past founder of a digital medicine company and from her many leadership positions. Access Rock Health’s 2020 Diversity in Digital Health report here!
Click here to listen to the recording!
Click here to view the presentation slides
This workshop highlighted key papers from the newly released Special Issue of Digital Biomarkers, sponsored by Evidation Health and DiMe.
Digital Health companies face a unique set of challenges and opportunities progressing from concept to commercialization. This DiMe webinar will cover strategic implications and decisions associated with evidence generation strategies, and specifically their impact on stakeholder adoption and commercialization/market access models. Listen in as our fantastic panel of speakers to dive deeper into this topic!
Click here to view the presentation slides
This workshop highlighted key papers from the newly released Special Issue of Digital Biomarkers, sponsored by Evidation Health and DiMe.
Presented by the lead authors themselves, we examined the latest advances in the Maturation of digital health capabilities, Emerging Applications in how to turn patient and person-generated health data into insights, and how the Talent landscape is developing. This webinar includes an open discussion where the panel shares their experience on data collection outside the clinic, and perspectives on how digital health can enter the clinical practice mainstream.
The workshop is of relevance to everyone interested in, or working on, implementing digital measures into clinical trials, RWE and clinical practice.
The sixth and final event in our 6-week educational series was presented by Ed Ramos and Katie Baca-Motes. Each week experts will:
– Guide you through different sections of The Playbook
– Demonstrate, through worked examples, how you can use this resource to develop and implement digital clinical measures at your organization
To learn more about The Playbook visit playbook.dimesociety.org
Click here to view The Playbook
The fifth event in our 6-week educational series was presented by Steve Steinhubl and Sofia Warner. Each week experts will:
– Guide you through different sections of The Playbook
– Demonstrate, through worked examples, how you can use this resource to develop and implement digital clinical measures at your organization
To learn more about The Playbook visit playbook.dimesociety.org
Click here to view The Playbook
The fourth event in our 6-week educational series was presented by Victor Chan, Priyanka Agarwal, and Thomas Switzer. Each week experts will:
– Guide you through different sections of The Playbook
– Demonstrate, through worked examples, how you can use this resource to develop and implement digital clinical measures at your organization
To learn more about The Playbook visit playbook.dimesociety.org
Click here to view The Playbook
The third event in our 6-week educational series was presented by Adam Brown, Dena Mendelsohn, and John WIlbanks. Each week experts will:
– Guide you through different sections of The Playbook
– Demonstrate, through worked examples, how you can use this resource to develop and implement digital clinical measures at your organization
To learn more about The Playbook visit playbook.dimesociety.org
Click here to view The Playbook
The second event in our 6-week educational series was presented by Andy Coravos, Chris Benko, and Christine Manta. Each week experts will:
– Guide you through different sections of The Playbook
– Demonstrate, through worked examples, how you can use this resource to develop and implement digital clinical measures at your organization
To learn more about The Playbook visit playbook.dimesociety.org
Click here to view The Playbook
The first event in our 6-week educational series was presented by Gina Valo and Jen Goldsack. Each week experts will:
– Guide you through different sections of The Playbook
– Demonstrate, through worked examples, how you can use this resource to develop and implement digital clinical measures at your organization
To learn more about The Playbook visit playbook.dimesociety.org
Click here to view The Playbook
Introducing the essential industry guide for successfully developing & deploying digital clinical measures across clinical research, clinical care, and population health.
Join colleagues from the Food and Drug Administration, Myokardia, Genentech, Scripps, Sage Bionetworks, Koneksa, Elektra Labs and the Digital Medicine Society as they unveil the first draft of this unprecedented, action-oriented guide.
Click here to learn more about The Playbook
Listen in as we introduce a new program from the US Department of Health and Human Services (HHS)’s Biomedical Advanced Research and Development Authority (BARDA). This is ENACT: Early Notification to Act, Control, and Treat. In this presentation you will:
– Learn how the US government partners with innovators to develop disruptive healthcare technologies with ENACT
– Discover ENACT’s goals: providing actionable health information to patients, healthcare providers, and public health organizations
– Explore how we can approach presymptomatic diagnostics of viral infections
Listen is as our expert panelists discuss the importance of sourcing diverse patient perspectives and clinical expertise, including ways to reach outside of our immediate network. This webinar:
– Discusses the special considerations that must be made in order to disrupt responsibly
– Provides the best practices and actionable steps on bridging knowledge gaps between healthcare innovators and experts
– Offers guidance to drive the adoption of viable, scalable solutions that meet the needs of both patients and providers
Listen in as our experts address how systemic racism persists in science and medicine, and what we can do about it.
– How systemic racism perseveres in the realm of scientific and medical research
– Clear examples of how systemic racism leads to inequity in healthcare, particularly harming Black patients
– Actionable solutions we can all take to dismantle systemic research and reach a more just future
Listen in as our experts define Digital Therapeutics and offer an overview of successful digital therapeutic product development and deployment:
– The current state of the industry
– Evidentiary requirements for creating impactful digital therapeutics
– Advice for successfully getting products to patients and creating a sustainable business model
This session addresses the importance of inclusivity within healthcare development and innovation teams. Listen to gain practical advice on:
– How to build an inclusive team — why it matters and overcoming the pipeline fallacy
– Creating and fostering inclusive workplace cultures
– Keys to successfully retaining talent
Listen as we discuss a brief history of diabetes care innovation as it relates to continuous glucose monitors (CGMs). Experts discuss examples of how machine learning (ML) is replacing retrospective approaches with proactive approaches in patient care, including:
– Case studies in how machine learning has improved care
– Applications for complex patients cohorts, including Type 2 patients
– Predictions for safer care and better management
The official release of the fully-updated version of the Xcertia mHealth App Guidelines provides two key areas of collaboration and education within the digital health marketplace. Listen as experts:
– Share experiences and lessons learned during the updating of the guidelines from the lens of the Xcertia Work Group Leaders
– Explore with the audience how the existence of the Xcertia Guidelines can create opportunities to drive market adoption and use.
The Collaborative for Recovery and Health works cooperatively with patient populations in co-designing meaningful and effective smartphone interventions. Listen to this resource to:
– Learn about the collaborative role of researchers and patients in digital health development and implementation.
– Understand the intersection between user-centered design and community-engaged research.
Learn about Sage Bionetworks’ Elements of Informed Consent toolkit and review:
– Use cases and real examples describing the Sage approach to the informed consent process, including eConsent.
– Prompt questions to make sure you’ve thought through your approach.
– Sage tools available to you to help support your development of consent documents when using digital medicine tools in research.
This webinar will provide a level set for healthcare professionals seeking to:
– Develop an understanding of machine learning methods
– Distinguish between machine learning and other computational approaches for digital health data
– Recognize opportunities to use machine learning to address challenges in healthcare